← FDA DRUG APPROVALS
FDA ANDA · ANDA215846
SODIUM NITROPRUSSIDE IN 0.9% SODIUM CHLORIDE
Sponsor: SLATE RUN PHARMA
APPLICATION
ANDA215846
TYPE
ANDA
ORIGINAL APPROVAL
2022-08-26
LATEST ACTION
2022-08-26
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
SODIUM NITROPRUSSIDEPrescription
SODIUM NITROPRUSSIDE 50MG/100ML (0.5MG/ML) · SOLUTION · INTRAVENOUS
SODIUM NITROPRUSSIDEPrescription
SODIUM NITROPRUSSIDE 10MG/50ML (0.2MG/ML) · SOLUTION · INTRAVENOUS
SODIUM NITROPRUSSIDEPrescription
SODIUM NITROPRUSSIDE 20MG/100ML (0.2MG/ML) · SOLUTION · INTRAVENOUS
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.